INCB018424 in Patients With Advanced Hematologic Malignancies
Status:
Completed
Trial end date:
2017-03-23
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if ruxolitinib can help to control
advanced hematological malignancies. The safety of this drug will also be studied.